key: cord-0785600-usyqkglg
authors: Malato, João; Sotzny, Franziska; Bauer, Sandra; Freitag, Helma; Fonseca, André; Grabowska, Anna D.; Graça, Luís; Cordeiro, Clara; Nacul, Luís; Lacerda, Eliana M.; Castro-Marrero, Jesus; Scheibenbogen, Carmen; Westermeier, Francisco; Sepúlveda, Nuno
title: The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: a meta-analysis of public DNA methylation and gene expression data
date: 2021-07-29
journal: Heliyon
DOI: 10.1016/j.heliyon.2021.e07665
sha: d9399fb82cd7335f08907d9179af412a8b30b035
doc_id: 785600
cord_uid: usyqkglg

People with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) often report a high frequency of viral infections and flu-like symptoms during their disease course. Since this reporting is in line with different immunological abnormalities and altered gene expression profiles observed in the disease, we aimed to explore whether the expression of the human angiotensin-converting enzyme-2 (ACE2), the major cell entry receptor for SARS-CoV-2, is also altered in this neglected clinical population. In particular, a low expression of ACE2 is usually indicative of a high risk of developing COVID-19. We then performed a meta-analysis of public data on CpG DNA methylation and gene expression of this enzyme and its homologous ACE protein in peripheral blood mononuclear cells and related subsets. We found that patients with ME/CFS have decreased methylation levels of four CpG probes in the ACE locus (cg09920557, cg19802564, cg21094739, and cg10468385) and of another probe in the promoter region of the ACE2 gene (cg08559914). We also found a decreased expression of ACE2 but not of ACE in patients with ME/CFS when compared to healthy controls. Accordingly, in newly collected data, we found evidence for a higher proportion of samples with an ACE2 expression below the limit of detection in patients with ME/CFS than in healthy controls. Altogether, patients with ME/CFS could be at a higher COVID-19 risk when infected by SARS-CoV-2. To further support this conclusion, similar research should be conducted for other human cell entry receptors and other cell types, namely, those mainly targeted by the virus.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a multifactorial and complex disease characterized by two main symptoms: (1) persistent but unexplained fatigue that is not alleviated by rest; and (2) post-exertional malaise upon minimal physical or even mental effort [1, 2] . Although its cause remains unknown, a growing body of evidence strongly associates ME/CFS with several microbial and viral infections, as potential trigger factors [3, 4] . In addition, it has been hypothesized that reactivations of latent viral infections also play a role [5, 6] due to several abnormalities at the level of the immune system [7] [8] [9] . On the molecular basis of the disease, peripheral blood mononuclear cells (PBMCs) show altered gene expression profiles [10] , including a decreased abundance of the human angiotensin-converting enzyme 2 (ACE2) [11] , the main cell entry receptor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [12] [13] [14] . Altogether this evidence raises the question about the COVID-19 risk in patients with ME/CFS.

As basic information, ACE2 is encoded by the X-linked ACE2 gene whose expression is predominant in the lungs, heart, skin, and kidneys [15] [16] [17] [18] . ACE2 expression can also be detected in monocytes [19] and activated macrophages [20] . However, the percentage of ACE2-expressing cells is below 5% in the main immune-cell populations [20] . Accordingly, current RNA-Seq studies suggest a lack of or limited ACE2 expression in PBMCs from healthy controls [18] . ACE2 has an amino-acid sequence identity of 41% with its homologous angiotensin-converting enzyme (ACE) [21] . This sequence similarity increases to 61% at the nucleotide level [21] . The enzymes ACE and ACE2 are members of the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and vascular resistance [22] . In particular, ACE and ACE2 have vasoconstriction and vasodilation effects, respectively. Given this counteracting effect, high ACE:ACE2 ratios were proposed as possible indicators of severe COVID-19 outcomes, linked to increased reactive oxygen species (ROS) production, vasoconstriction, and inflammation [23] .

To answer our research question, we performed a meta-analysis of public DNA methylation and gene expression data of ACE2 and ACE in PBMCs. Our analysis is in line with a similar study on the DNA methylation pattern of ACE2 in PBMCs from patients with systemic lupus erythematosus [24] , an autoimmune disease whose symptoms overlap with the ones from ME/CFS [25] . To complement our findings, we also compared the mRNA levels of these two genes in PBMCs from a new cohort of female patients with ME/CFS and healthy women.

In our meta-analysis, we selected public data from studies using either the 1994 Centre for Diseases Control criteria (1994 CDC/Fukuda) [1] or the 2003 Canadian Consensus Criteria (2003 CCC) [2] for the disease diagnosis. These criteria are defined by the presence of several key symptoms while excluding known medical conditions (e.g., multiple sclerosis or lupus) that could explain fatigue.

The choice of using these two criteria for study selection is in line with the research standards suggested by the European Network on ME/CFS [26] .

Our meta-analysis was based on six genome-wide DNA methylation association studies ( Table 1) , four of which [27] [28] [29] [30] were previously reviewed [31] , and two others published after this review [32, 33] . Briefly, these studies aimed to identify differentially methylated CpG dinucleotide sites between patients and healthy controls. Illumina methylation arrays were used to measure the respective DNA methylation levels except for a single study (Table 1 ). In this study, it was used the reduced representation bisulfite sequencing [33] .

With respect to the exclusion criteria, one study excluded any recruited individual who was taking any beta-blockers or ACE inhibitors [30] . Three studies excluded potential participants who were taking any medication with immunomodulatory effects or affecting the underlying DNA methylation levels [28, 29, 32] .

In four of the published DNA methylation studies, patients and healthy controls were matched for age, gender, and body mass index (Table 1) [28] [29] [30] . In two other studies, the matching was only based on age and gender [27, 33] . Ethnicity was also used for further matching [30, 32] or it could be assumed in studies in which the recruitment only contemplated white females [28, 29] . The DNA methylation levels were quantified in CD4+ T cells [27] , PBMCs [28] [29] [30] 33] , and T lymphocytes [32] .

We conducted a joint analysis of the four array-based studies which made the data available [28] [29] [30] 32] . We first retrieved the data from all the CpG probes located in the coding regions and the transcription starting sites (TSS) of ACE and ACE2, respectively. We then restricted our data analysis to the 27 probes shared between the Infinium HumanMethylation450K and the Infinium HumanMethylationEPIC arrays (Supplementary Table 1 ).

Before conducting the statistical analysis itself, we checked whether (1) the selected probes exhibited a high probability of detection, (2) they were not cross-reactive with other genomic regions, and (3) they were not affected by single nucleotide polymorphisms (SNPs) with high minor allele frequencies [34] . In the latter criterion, the SNPs included in the selected probes had a minor allele frequency less than 5% in Europeans and North Americans ( Figure 1A ; Supplementary Table J o u r n a l P r e -p r o o f 2) referring to the sampled populations of the studies. All probes passed the remaining basic quality control checks.

We analyzed the M-values of a given probe instead of the respective -values to ensure a good approximation of the Normal distribution to the data [35] . Briefly, the -values were calculated as the proportion of the methylation signal relative to the total signal for a given probe. The M-values were finally obtained by applying a logit transformation to the -values.

To analyze the M-values of each probe, we initially estimated a linear regression model where the respective covariates were the study and disease status indicators of the participants. In this model, we included not only the main effects of the covariates but also the respective interaction term. The model parameters were then estimated by the maximum likelihood method. Note that the main effect of the disease status is usually seen as the pooled effect of this covariate across all studies, as done in meta-analysis.

We then simplified the model using a backward stepwise procedure based on Akaike's information criteria. Since the effect of the study indicator was significant for the data of each probe, we tested the association between ME/CFS and a given probe using a likelihood ratio test. In this test, we compared the model including the study indicator only with the best model including that covariate and the one associated with disease status (i.e., either a model only including the main effects or a model including both main effects and the respective interaction term).

To control for multiple testing, we adjusted the raw p-values using the Benjamini-Hochberg procedure [36] . This adjustment ensured a false discovery rate of 5% under the assumption of independent tests. Pearson's correlation coefficient was used to check the validity of this assumption.

We also repeated the same association analysis for women and men separately. Note that three studies only recruited women [28] [29] [30] while the remaining study recruited both men and women [32] . In the latter study, there was no information available about the gender of each participant. In this case, we estimated this missing information using the function getSex of the R package minfi applied to the genome-wide DNA methylation data [37] . The resulting frequencies of men and women matched with those reported in the original study.

In the women-specific analysis, we performed the same association analysis as described above. In the men-specific analysis, we compared a linear regression model with the disease status as the single covariate against another model without that covariate when analyzing data from each probe.

The comparison was done by the likelihood ratio test whose p-values were then adjusted for multiple testing in the same way as described above.

Finally, for the study which did not share the respective data [27] , we checked whether the reported differentially methylated CpG probes were located in either ACE or ACE2 (see Table 1 from this J o u r n a l P r e -p r o o f study). We did the same for the study based on the reduced representation bisulfite sequencing technology [33] (see Additional File 1 from this study).

Our meta-analysis of this type of studies was focused on eight reports using microarray technology (Table 2 ) [11, [38] [39] [40] [41] [42] [43] [44] . These studies complied with the Minimum Information about a Microarray Experiment (MIAME) standard [45] and, therefore, they were considered to have sufficient quality for their inclusion in the meta-analysis. In particular, these studies normalized the data which ensured comparability between different samples and between different measurements of the same genes.

Gene expression of these studies was quantified in PBMCs (5 studies), whole blood (2 studies) and muscle biopsies (one study). One study excluded any participant who was taking any regular medication [43] . Another study conducted a review of the medications taken by the study participants at the time of data collection [11] . However, it was unclear which medication was considered as a criterion of exclusion. A third study reported that healthy controls were free from any medication at the time of sampling [41] .

Three additional studies using microarray technology [46] [47] [48] were excluded from our study due to unclear or ineligible case definitions of ME/CFS. We also excluded four RNA-seq studies [49] [50] [51] [52] , because of insufficient reporting on the basic quality control checks. In particular, these studies did not report the percentage of reads that could be mapped onto the reference transcriptome, the percentage of the transcriptome covered, the average number of mapped reads per transcript, the relationship between the GC content and the mapped read distribution, as recommended elsewhere [53] . Additionally, given the high sequence homology between ACE and ACE2, these studies did not explain how their mapping algorithms dealt with reads that could be mapped onto different locations in the transcriptome.

The selected studies were conducted in small cohorts of patients with ME/CFS (mean sample size=18.5; range=4-37) and healthy controls (mean sample size=18.6; range=5-50 individuals) ( Table 2 ). In these studies, the patients and healthy controls were matched for age and gender. Different commercial and custom microarray technologies were used for the respective gene expression quantification. There was only one study in which the microarray did not include any probe in the genes of interest [38] . Another study used a custom array based on 9,522 genes from the RefSeq database as available in August 2002 [39] . However, it was unclear whether the expressions of ACE and ACE2 were in fact measured, because the study did not provide the list of genes included in the respective microarray. In terms of data sharing, one study made the data J o u r n a l P r e -p r o o f available [43] and another one within the respective publication [41] . The latter study used a custom microarray that measured the expression of stress-related genes including ACE but excluding ACE2.

Before conducting a meta-analysis of the available data, we first re-analyzed two studies where the normalized data were available [41, 43] . In the first study [41] , we calculated the mean of the log2(fold-change) for ACE and the respective standard error. Note that the microarray used in this study did not include any probe in ACE2. In the second study [43] , we initially calculated the mean and the respective standard error of the log2(fold-change) for each probe located in ACE and ACE2.

We then pooled each pair of means for the same gene using the inverse-variance weighting method [54] . A third study reported the mean of the log2(fold-change) for ACE2 and the respective p-value using a two-tailed Student's test [11] . In this case, we determine the quantile of the t-distribution associated with half of the reported p-value, equated it to the test statistic, and solved the resulting equation as a function of the standard error. No information was available from this study concerning the expression levels of ACE.

Finally, we pooled the different estimates for the same gene from different studies using the inverse-variance weighting method [54] .

Thirty-seven women with ME/CFS were recruited in 2020 from the outpatient clinic for immunodeficiencies at the Institute for Medical Immunology at the Charité-Universitätsmedizin Berlin, Germany. These patients were diagnosed according to the 2003 CCC while excluding other medical or neurological diseases which could explain fatigue [2] . Thirty-four women with selfreported healthy status were recruited from staff.

Consistently with previous studies of ME/CFS, the gene expression quantification was performed in PBMCs. These cells were isolated from heparinized whole blood by density gradient centrifugation using Biocoll Separating Solution (Merck Millipore). Total RNA was isolated and extracted from 210 6 PBMCs according to the manufacturer's instructions (NucleoSpin RNA Kit, Macherey-Nagel, cat. nr. 740955.50). Afterwards cDNA was prepared by reverse transcription (High-Capacity increased to 100 ng. All measurements were performed with the ABI7200 and software Step One Plus as absolute quantification according to manufacturer's instruction. Relative gene expression was analysed using the ΔCT method.

We first tested whether patients and healthy controls were matched for age using the Kolgomorov-Smirnov test for two independent samples. For a matter of statistical convenience, gene expression values were independently transformed for ACE and ACE2 using a Box-Cox transformation [55] .

The parameter estimates of this transformation were 0.303 and 0.225 for ACE and ACE2, respectively. The transformed values for each gene were then analyzed as the outcome variable of a linear regression model specifying age and disease status of the participants as the respective covariates. The linear regression model was estimated using the maximum likelihood method. After estimating the models, we tested the normal distribution in the resulting residuals using the Shapiro-Wilk test. We also visually inspected the assumption of constant variance of the same residuals as a function of the covariates.

Note that we were unable to quantify the ACE2 expression in 11 patients due to cDNA material below the limit of detection. These problematic samples could be due to a lower expression of ACE2 in ME/CFS patients than in healthy controls. To test this hypothesis, we compared the respective proportion of samples below the limit of detection using the Pearson's  2 test for twoway frequency tables.

The significance level of the statistical analysis was set at 5%.

The protocol of this study was approved by the Ethics Committee of Charité-Universitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments (reference number EA2/067/20). All patients and healthy controls gave written informed consent to participate in the study.

We performed our statistical analysis in the R software version 4.0.3. In this analysis, we used the following Bioconductor packages: hgu133a.db, hgu133plus2.db, IlluminaHumanMethylation450kanno.ilmn12.hg19, and IlluminaHumanMethylationEPICanno.ilm10b2.hg19 to retrieve the annotation of the GeneChip HG-U133A, GeneChip U133+2, Infinium HumanMethylation450K Array and HumanMethylationEPIC arrays, respectively; minfi to estimate the sex of each individual from J o u r n a l P r e -p r o o f DNA methylation data [37] . The R scripts are freely available from the first and last authors upon request.

The oldest DNA methylation study [27] did not make the data available and hence, we screened the list of 120 differentially methylated probes (see Table 1 from this study). Although located in 70 genes, these probes were neither located in ACE nor ACE2. We also screened the list of differentially methylated probes reported by the study based on the reduced representation bisulfite sequencing technology (see Additional File 1 from ref. [33] ). Again, none of these probes was in the ACE or ACE2 loci.

For the four array-based studies [28] [29] [30] 32] , we conducted a joint analysis of the respective data in accordance with a meta-analysis. We first observed that the M-values of the 27 probes under investigation tended to be uncorrelated with each other ( Figure 1B ). This observation supported the use of the Benjamini-Hochberg procedure to adjust the raw p-values under a multiple testing scenario.

The subsequent analysis suggested four CpG probe in ACE to be associated with ME/CFS ( Figure   1C ). The probe cg09920557 belongs to the TSS region of the gene while the remaining probes (cg19802564, cg21094739, and cg10468385) are spread over the gene body. The best linear regression models for each probe included both the main effects of the study indicator and of the disease status and the respective interaction term (Supplementary Table 3 ). The statistical interaction between these two covariates could be seen when plotting the whole data set ( Figure   2A ). Although not significant, the estimated main effect of the disease status was negative for each of the significantly associated probes.

Concerning the probes in ACE2, the only significant association with ME/CFS was obtained for cg08559914 located in the TSS region of the gene ( Figure 1C ). According to the best linear regression model for this probe, there was a negative association between the respective M-values and ME/CFS (coefficient estimate= -0.141 with a standard error of 0.048; Figure 2B and Supplementary Table 3 ). Given that a hypomethylated promoter region is typically indicative of an increased expression of the respective gene, this finding suggested an increased ACE2 expression in patients with ME/CFS. We then repeated the same analysis for women and men separately. For women, we obtained the same disease associations, as described above ( Figure 1D and Supplementary Table 3 ). For men, we did not find any significant associations probably due to data from a single study [32] (Figure 1E ).

We first conducted a re-analysis of the two studies in which the expression levels of ACE or ACE2 were available for each participant ( Figure 3A ) [41, 43] . In the first study [41] , there was evidence for an increased expression of ACE in patients with ME/CFS (mean of the log2(fold-change)= 0.265; 95% CI=(0.089;0.441)). In the second study [43] , the means of the log2(fold-change) were estimated at 0.012 (95% CI=( -0.012;0.036)) and 0.004 (95% CI=(-0.014;0.022)) for the two probes in ACE. The corresponding estimates for the two probes in ACE2 were -0.038 (95% CI=(-0.085;0.009)) and -0.037 (95% CI=(-0.083;0.008)) ( Figure 3A ). The pooled estimates for this study were 0.007 (95% CI=(-0.006;0.020)) and -0.038 (95% CI=(-0.067;-0.008)) for ACE and ACE2, respectively.

Although not sharing the data, there was a study [11] that reported a significant negative association between ME/CFS and ACE2 expression (see online Supplementary Table 2 of this study). In this case, we obtained the following mean of the log2(fold-change)= -2.396 and 95% CI=( -4.518; -0.273).

We then pooled the estimates from different studies for the same gene: 0.008 (95% CI=(-0.005;0.021)) and -0.038 (95% CI=(-0.068;-0.009)) for ACE and ACE2, respectively ( Figure 3B ). Therefore, our meta-analysis suggested a reduced expression of ACE2 but not of ACE in patients with ME/CFS when comparing to healthy controls.

Finally, the remaining gene expression studies neither shared the respective data nor reported any differential ACE/ACE2 expression between patients and healthy controls.

To complement our findings from the above meta-analysis, we measured the ACE and ACE2 mRNA levels in PBMCs from 37 women with ME/CFS (mean age = 41.1 years old) and 34 healthy women (mean age = 37.4 years old) ( Table 3) . Patients and healthy participants were matched for age (Kolmogorov-Smirnov test, p=0.38). There was no information about the disease duration for 4 patients. The average disease duration for the remaining patients was 5.4 months in relation to the time of diagnosis (range = 0-24 months).

We observed higher mRNA levels of ACE than of ACE2 (Table 4, Figure 4A ). There was no evidence for a significant correlation between ACE and ACE2 expression levels (Spearman's correlation coefficient = -0.120) ( Figure 4B ). In contrast to the above meta-analysis, we could not find a reduced expression of ACE2 in patients with ME/CFS using the complete case scenario (Table 4 ). However, there were 29.7% (11 out 37) of the samples from patients in which the expression level of ACE2 was below the limit of detection. This proportion of samples was significantly higher than that for healthy controls given that the expression of ACE2 could be J o u r n a l P r e -p r o o f quantified in all the samples (29.7% versus 0%; Pearson's  2 test, p=0.002). Consequently, we could not rule out that the patients with ME/CFS from this cohort have a decreased expression of ACE2 when compared to healthy controls. Finally, in accordance with our meta-analysis, there was no evidence of differential expression of ACE between patients and healthy controls from this cohort.

We attempted to identify differences in ACE/ACE2 DNA methylation and expression levels between patients with ME/CFS and healthy controls. With the identification of these differences, we expected to understand the health risk of patients with ME/CFS if infected by SARS-CoV-2.

However, we stumbled upon hurdles related to (1) data unavailability for a possible re-analysis, (2) availability of data derived from PBCMs and related subsets in which ACE2 is not particularly expressed, (3) studies with unclear data quality, and (4) studies using disease diagnostics that are not recommended for research. As a consequence, we could not provide a more definite answer to our main research question.

Notwithstanding the difficulties in conducting our study, we could identify four CpG probes on ACE and another one on ACE2 with decreased DNA methylation levels in patients with ME/CFS. This finding suggested an increased expression of the respective genes. However, our meta-analysis of public data suggested the opposite. Such decrease in ACE2 expression was partially confirmed by new data in which there was evidence for a higher proportion of samples below the limit of detection in patients with ME/CFS than in healthy controls. Nonetheless, it was clear that ACE2 is not particularly expressed in PBCMs from both patients with ME/CFS and healthy controls, as alluded in the introduction.

In general, ACE2 downregulation is known to occur after host-cell entry by SARS-CoV-2 [56] .

This downregulation is particularly problematic in individuals affected by cardiovascular diseases, diabetes, and other medical conditions, due to their low ACE2 levels before the infection [57] .

SARS-CoV-2 infection is then expected to further increase the ACE:ACE2 ratio, thus, promoting vasoconstriction, increased production of ROS and inflammation in patients with these comorbidities [23] . In this scenario, a putative reduction of the ACE2 expression makes patients with ME/CFS similar to these patients with a high risk for COVID-19. The fundamental question is then 

Given the lack of or reduced ACE2 expression in PBMCs, one is tempted to say that SARS-CoV-2 does not infect these cells. However, earlier studies on SARS-CoV-1 found this virus within T lymphocytes, macrophages, and dendritic cells [61] . More recently, an in vitro study was able to infect PBMCs with SARS-CoV-2 [62] . Monocytes are particularly susceptible to such infections. In this context, one cannot rule out that SARS-CoV-2 might use alternative receptors when infecting PBMCs.

Among the alternative receptors for SARS-CoV-2, the human transmembrane protease serine 2 (TMPRSS2) was suggested as a strong candidate [63] due to its role on SARS-CoV-1 infection [64, 65] . This protease seems to induce SARS-CoV-2 cell entry through endocytosis via a mechanism of ACE2 cleavage [14] . Another candidate receptor is the A disintegrin and metallopeptidase domain 17 protein (ADAM17) recognized by the immune system as a stressresponse signal [66] . Like TMPRSS2, ADAM17 can also cleave ACE2 but with a reduced viral invasion efficiency [67] .

With respect to the role of these proteases in ME/CFS, a targeted gene expression study analyzed ADAM17 and other stress-response proteins [41] . This study did not report any differential expression of this protease between patients with ME/CFS and healthy controls. However, this study is likely to be affected by a low statistical power due to small sample sizes for both groups. In addition, one of the selected DNA methylation studies suggested a decrease in the DNA methylation levels of one ADAM17-related CpG probe in patients with ME/CFS [30] .

Dipeptidyl peptidase-4 (DPP4), also known as the lymphocyte cell surface protein CD26, was found to be the main receptor for the Middle East respiratory syndrome-related coronavirus [68, 69] . In contrast to ACE2, this surface protein is highly abundant in PBMCs including CD4+ and CD8+ T cells [18] . Bioinformatic analysis also suggested a strong interaction potential between this protein and SARS-CoV-2 [70, 71] . Finally, DPP4 inhibitors were found to be protective against severe COVID-19 in patients with diabetes mellitus when compared to RAAS blockers [72] . After some initial concerns, this finding combined with many others suggested an interesting therapeutic avenue against COVID-19 using DPP4 blockers [73] .

Interestingly, there is evidence for an increased proportion of natural killer cells and T cells expressing DPP4/CD26+ in patients with ME/CFS [7, 74] . However, the number of DPP4/CD26 molecules was significantly reduced in T lymphocytes and natural killer cells of these patients [74] .

If DPP4 is truly an important receptor for immune-cell invasion by SARS-CoV-2, research about this receptor should be prioritized when analyzing PBMCs from patients with ME/CFS.

Sialic acids were also hypothesized as binding receptors used by SARS-CoV-2, as reported for other human coronaviruses [75] . These acids are highly expressed in the epithelium cells of the lungs and oral cavity [76] . In vitro and in silico studies demonstrated the same binding potential for J o u r n a l P r e -p r o o f acids on ACE2 receptor prevent ACE2-virus interaction [80, 81] . Again, detailed research on these putative receptors could help to determine the health risk of patients with ME/CFS when infected by SARS-CoV-2.

It was suggested that the arousal state experienced by patients with ME/CFS could protect them against microbial infections [82] . This suggestion came from a clinical trial where patients were treated with clonidine to decrease such state. Treated patients got their symptoms worsened and had their inflammation markers increased during the trial. In contrast, basic epidemiological studies reported many patients with frequent viral infections and flu-like symptoms [3, 4, 83] . The question is how an infection by SARS-CoV-2 lies in this contrasting evidence. A possible answer can be given with the assistance of the so-called sustained arousal model of ME/CFS [84] . According to this model, a sustained arousal state promotes in the long-run deleterious alterations of the normal function of different body systems, including the immune system. Similar prediction was made by a recent study discussing the natural history of ME/CFS [85] . If so, patients with a longer burden of the disease are more likely to show these immunological alterations than patients at the early stages of the disease. However, we could not analyze the effect of disease duration on our results, because this variable was not available in the public data sets included in our meta-analyses.

Finally, our original idea was to perform a meta-analysis of ACE/ACE2 data from published genome-wide association studies on ME/CFS [11, 32, [86] [87] [88] . However, we could not materialize this idea, because such studies did not make their data publicly available. Nevertheless, evidence is scarce for a putative role of ACE/ACE2 polymorphisms on ME/CFS. Two studies reported many candidate SNPs for such association, but none was located in ACE or ACE2 [11, 86] . Two other studies did not find any significant SNPs associated with ME/CFS [32, 88] . The most optimistic study reported thousands of SNPs related to the disease [87] . However, this study did not perform all the basic quality control checks [89] .

Notwithstanding the low expression of ACE2 in PBMCs in general, there is evidence for a decreased expression of the gene in these cells from patients with ME/CFS. If PBMCs can qualitatively recreate what is occurring in the main cell targets of SARS-CoV-2, then patients with this disease could be at a higher COVID-19 risk. Therefore, future research should prioritize the collection of data from these main cellular targets in patients with ME/CFS. Further investigation should be also conducted on alternative SARS-CoV-2 receptors (i.e., DPP4 and sialic acids). At last, future research should also consider investigating putative sex differences in patients with ME/CFS given that, in general, men are more affected by COVID-19 than women [90] . (B) Forest plot for the study-specific and pooled estimate of the mean of the log2(fold-change) between patients with ME/CFS and healthy controls using data shown in A.

Analysis of ACE and ACE2 expression levels from the German study. (A) Violin plots of ACE (left side) and ACE2 (right side) mRNA raw data (upper row) and transformed data using a Box-Cox transformation (lower row). Green-filled plots represent the cohort of healthy controls and rosefilled plots represent the ME/CFS-diagnosed patients. (B) Scatterplot between the transformed ACE and ACE2 expression levels (Spearman's correlation coefficient = -0.120).

J o u r n a l P r e -p r o o f 

The chronic fatigue syndrome: A comprehensive approach to its definition and study

Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols

Epidemiological characteristics of chronic fatigue syndrome/myalgic encephalomyelitis in Australian patients

Onset patterns and course of myalgic encephalomyelitis/chronic fatigue syndrome

Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Myalgic encephalomyelitis/chronic fatigue syndrome: The human herpesviruses are back!

Immunologic abnormalities in chronic fatigue syndrome

Immunological aspects of chronic fatigue syndrome

Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis

Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2)

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Human monocyte subsets exhibit divergent angiotensin I-converting activity

Little to no expression of angiotensin-converting enzyme-2 on most human peripheral blood immune cells but highly expressed on tissue macrophages

A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captoprilinsensitive carboxypeptidase

Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9

A Key Also in 2019 Coronavirus Disease (Covid-19)?, Front. Med. 7 (2020)

Epigenetic dysregulation of ACE2 and interferonregulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients

Infection elicited autoimmunity and Myalgic encephalomyelitis/chronic fatigue syndrome: An explanatory model

The Development of a Consistent Europe-Wide Approach to Investigating the Economic

Methylation Profile of CD4+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

DNA methylation modifications associated with Chronic Fatigue Syndrome

Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Identification of myalgic encephalomyelitis/ chronic fatigue syndrome-associated DNA methylation patterns

Epigenetic Components of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Uncover Potential Transposable Element Activation

Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions

A comprehensive overview of Infinium HumanMethylation450 data processing

Comparison of Betavalue and M-value methods for quantifying methylation levels by microarray analysis

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

Exercise responsive genes measured in peripheral blood of women with Chronic Fatigue Syndrome and matched control subjects

Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome

Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis

Identification of marker genes for differential diagnosis of chronic fatigue syndrome

Transcription profile analysis of vastus lateralis muscle from patients with chronic fatigue syndrome

A gene signature for post-infectious chronic fatigue syndrome

Treatment Avenues in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Split-gender Pharmacogenomic Study of Gene-expression Modules

Minimum information about a microarray experiment (MIAME) -Toward standards for microarray data

Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections

Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome

Whole blood gene expression in adolescent chronic fatigue syndrome: An exploratory cross-sectional study suggesting altered B cell differentiation and survival

RNA-seq analysis of gene expression, viral pathogen, and b-cell/t-cell receptor signatures in complex chronic disease

Whole blood human transcriptome and virome analysis of ME/CFS patients experiencing post-exertional malaise following cardiopulmonary exercise testing

Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis/chronic fatigue syndrome

Bleeker-Rovers, A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome

A survey of best practices for RNA-seq data analysis

Statistical meta-analysis with applications

Estimating Box-Cox power transformation parameter via goodnessof-fit tests

SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Gene Expression Profiles of Peripheral Blood Mononuclear Cells Reveal Transcriptional Signatures as Novel Biomarkers of Cardiac Remodeling in Rats With Aldosteronism and Hypertensive Heart Disease

Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes

Gene expression profiles displayed by peripheral blood mononuclear cells from patients with type 2 diabetes mellitus focusing on biological processes implicated on the pathogenesis of the disease

The trinity of COVID-19: immunity, inflammation and intervention

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response

Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2

The metalloprotease ADAM17 in inflammation and cancer

TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein

Host Species Restriction of Middle East Respiratory Syndrome Coronavirus through Its Receptor, Dipeptidyl Peptidase 4

Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations

Biomarkers in chronic fatigue syndrome: Evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26

The role of cell surface sialic acids for SARS-CoV-2 infection

Glycan recognition at the saliva -oral microbiome interface

In-Silico evidence for two receptors based strategy of SARS-CoV-2

The sialoside-binding pocket of SARS-CoV-2 spike glycoprotein structurally resembles MERS-CoV

The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device

Host and viral determinants for efficient SARS-CoV-2 infection of the human lung

Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration

Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome a combined cross-sectional and randomized clinical trial

Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: A cross-sectional study

Can sustained arousal explain the Chronic Fatigue Syndrome?

How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS

Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome

Genetic predisposition for immune system, hormone, and metabolic dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: A pilot study

Genetic risk factors of ME/CFS: A critical review

Review of the Quality Control Checks Performed by Current Genome-Wide and Targeted-Genome Association Studies on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses